Fortesta Available for Testosterone Deficiency
Fortesta (testosterone gel) has been made available by Endo Pharmaceuticals for treating hypogonadism, also referred to as low testosterone (Low T), in men ≥18 years.
Hypogonadism
Phase 2b study of Androxal for the treatment of secondary hypogonadism
Repros Therapeutics reported it has received Institutional Review Board (IRB) approval to commence a Phase 2b study of Androxal (enclomiphene) in men with secondary hypogonadism.
Fortesta approved for testosterone deficiency
Endo Pharmaceuticals announced that the FDA has approved Fortesta (testosterone gel) for the treatment of hypogonadism, also referred to as low testosterone (Low T) in men ≥18yrs.
Axiron approved for testosterone deficiency
The FDA has approved Axiron (testosterone topical solution, from Eli Lilly and Acrux) for replacement therapy in men ≥18yrs for conditions associated with a deficiency or absence of endogenous testosterone.
